No abstract

No abstract

used for any missing data. Secondary endpoint was the percentage improvement in the Dermatology Life Quality Index (DLQI). Other parameters include percentage improvement of the Numerical Rating Scale for Itch (NRS), BSA, and PASI. One patient was excluded for the DLQI analysis due to a protocol deviation at baseline.

Generalized pustular psoriasis is a relatively rare variant of psoriasis characterized by diffuse eruption of sterile pustules on an erythematous background. Untreated flares can result in life-threatening complications including sepsis and organ failure. Generalized pustular psoriasis has historically proven challenging to treat with an unpredictable clinical course and paucity of reliably efficacious treatment options. Until recently, there have been no FDA-approved therapies for generalized pustular psoriasis in the United States. In September 2022, the IL-36 receptor antagonist spesolimab became the first FDA-approved treatment for generalized pustular psoriasis in adults. We present a case of generalized pustular psoriasis with complete and rapid response to spesolimab.